Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

Ashraf Raslan, MD, Dorian Infantino, MD, Roman Zuckerman, DO, & Daniel Berlin, MD  |  Issue: November 2021  |  November 14, 2021

The biopsy of the right temporal artery with hematoxylin and eosin (H&E) staining was unremarkable.

Figure 1. The biopsy of the right temporal artery with hematoxylin and eosin (H&E) staining was unremarkable.

Sarah2 / shutterstock.com

Giant cell arteritis (GCA) is a granulomatous vasculitis of large- and medium-sized arteries, usually affecting the cranial branches of the aortic arch. It is the most common vasculitis, with the highest risk factor being age. Accurate diagnosis and prompt initiation of therapy are of great importance to prevent serious complications, with the most feared being permanent vision loss.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The diagnosis is suspected clinically based on characteristic symptoms and laboratory findings, and confirmed histologically by temporal artery biopsy.

A classical presentation is easy to recognize when a patient older than 50 presents with a new-onset headache along with other characteristic findings, such as jaw claudication, symptoms of polymyalgia rheumatica (PMR) and elevated inflam­matory markers. In clinical practice, however, GCA often presents diagnostic and management challenges.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

These challenges arise from different factors, including:

  • An atypical presentation (e.g., no headaches or atypical headaches, normal inflammatory markers or rare presenting symptoms, such as tongue or limb claudication, chronic cough, vertigo or oculomotor nerve palsy);
  • A negative temporal artery biopsy despite the high probability of the disease based on clinical presentation. In this case, the clinician has to make the difficult decision to continue high-dose steroid therapy, which comes with the potential of serious adverse effects, or to stop therapy and risk serious complications, such as permanent vision loss;
  • Temporal arteritis due to another form of systemic vasculitis, such as anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis or polyarteritis nodosa (PAN); or
  • Intolerance to high-dose steroid therapy.

We present a case that highlights some of these challenges and provide some clinical pearls that can help in the diagnosis and management of GCA.

Case Presentation

Our patient is a 78-year-old woman with a past medical history of hypertension and osteoporosis. She initially presented to the emergency department with new-onset neck pain and headache that started after a long bus ride one week earlier.

The pain started as a right-sided pos­terior neck pain, which radiated to the right occipital scalp and then anteriorly toward the right frontal area. She described the pain as intermittent, sharp, shooting and severe, at times.

She had no constitutional symptoms, jaw claudication or proximal myalgias. Her neurological examination was normal. Magnetic resonance imaging (MRI) of the brain was obtained because of her acute-onset, severe headache, but was unremarkable. MRI of the cervical spine showed age-related degenerative changes.

Her laboratory evaluation was significant for a markedly elevated erythrocyte sedimentation rate (ESR) of 73 mm/hr (reference range [RR]: 0–15 mm/hr) and C-reactive protein (CRP) of 87 mg/L (RR: <5–10 mg/L).

She underwent a unilateral right temporal artery biopsy (see Figures 1&2, above and opposite) and was started on 60 mg of prednisone daily for suspected GCA. Her headaches mildly improved, but her temporal artery biopsy result was did not demonstrate evidence of vasculitis. Given her negative biopsy results, GCA was considered unlikely, and the prednisone was tapered off over two weeks.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsVasculitis Tagged with:case reportGiant Cell Arteritistocilizumab

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Experts Discuss Proposed Giant Cell Arteritis Risk Tool

    April 26, 2018

    A proposed model to predict the risk of giant cell arteritis (GCA) prior to a temporal artery biopsy could help triage patients and guide decision making about the need for biopsy or monitoring (see Figure 1). There’s no specific biomarker for GCA, and GCA can be a “diagnostic conundrum, especially when it presents in an…

    Updates on Giant Cell Arteritis

    March 19, 2018

    SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…

    Giant Cell Arteritis Challenging to Diagnose, Manage

    March 1, 2015

    Common form of primary vasculitis difficult to identify, treat, but latest research suggests potential new therapeutic targets

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences